Vaxart, Inc. (NASDAQ:VXRT) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET

Company Participants

Ed Berg - SVP & General Counsel
Steven Lo - CEO
Sean Tucker - Founder & Chief Scientific Officer
James Cummings - Chief Medical Officer
Phil Lee - CFO

Conference Call Participants

Elaine Kim - Cantor Fitzgerald

Operator

Greetings and welcome to the Vaxart Business Update and Second Quarter 2024 financial results, conference call, a question and answer session will follow management's opening remarks. Individual investors may submit written questions to IR at vaxart.com As a reminder, this conference is being recorded.

I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel

Ed Berg

Good afternoon and welcome to today's call. Joining us from Vaxart are Steven Lo, Chief Executive Officer, Dr Sean Tucker, Founder and Chief Scientific Officer. Dr James Cummings, Chief Medical Officer, and Phil Lee, Chief Financial Officer.

Before we begin, I would like to remind everyone that during this conference call, Vaxart are may make forward looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could materially differ from those discussed in these forward looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the risk factors section of Vaxart's most recently filed annual report on Form-10k, and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward looking statements after the date of this call.

I'll now turn the call over to Steven Lo. Steve?

Steven Lo

Thanks, Ed, and thanks to all of you for joining us this afternoon. Today, I look forward to sharing updates on the recent progress that we have made for both COVID and norovirus programs and detailing our upcoming milestones. I'll then turn the call over to James for a more in-depth discussion of our planned BARDA funded phase 2b COVID trial and conversations with FDA for norovirus. Finally, Phil will cover our financial update before we open the call for your questions.

Since I joined Vaxart in March, I've had the opportunity to spend time with all of the functions in our company, and can confirm a deep commitment to advancing our science and to focusing on driving execution across the entire organization, it has been a strategic imperative of ours, particularly given the challenges of a biotech company that's innovating groundbreaking technology. This technology is also the reason why I joined Vaxart. I believe in the transformational potential of our oral pill vaccine platform.